Top private equity funds in China expose the 'US stock report': the proportion of Chinese concept stocks continues to rise, with PDD Holdings and Apple being the focus of differences in components.
In the third quarter of this year, most Chinese private equity firms, such as Hillhouse, Gao Yi, and Jinglin, remained focused on Chinese concept stocks. However, Hillhouse and Jinglin chose to reduce their shareholding in pdd holdings, while Gao Yi opted to continue increasing its stake in pdd holdings.
How do foreign investors adjust their positions in Chinese stocks? Alibaba and jd.com frequently appear in the news, while Buffett builds his position to 'lift' a Hong Kong stock.
① The 13F quarterly reports for US stocks have been released. How are Wall Street institutions adjusting their positions on Chinese stocks? ② Buffett's investment in domino's is boosting a Hong Kong stock. What are the highlights?
Bank of America Securities has lowered the target price of beigene (06160.HK) to 125 yuan and rated it as "neutral".
Bank of America Securities released a report indicating that considering beigene (06160.HK) performance in the first three quarters, the forecast for the research and development expense ratio for 2024 to 2026 has been raised by 1.4, 1.9, and 1.6 percentage points respectively, along with an increase in the forecast for sales, general, and administrative expense ratios by 2, 1.6, and 1.4 percentage points during the same period. Due to the robust progress in the solid tumor pipeline, long-term revenue forecasts have also been raised. Bank of America Securities has slightly lowered the target price for beigene's Hong Kong stocks from HKD 126.2 to HKD 125 to reflect the increased expenses. It maintains a "neutral" rating to reflect smooth progress in new drug development but acknowledges the competitive domestic market.
beigene (06160.HK) plans to change its English name to BeOne Medicines Ltd.
Beigene (06160.HK) announced the proposal to change the company's English name from 'BeiGene, Ltd.' to 'BeOne Medicines Ltd.', while the Chinese name will remain unchanged. (vc/w)~
bocom intl: raised beigene (06160) target price to 159 Hong Kong dollars. Q3 product sales and operation continue to improve.
Bocom Intl has raised Beigene's revenue forecasts for 2024-2026 by 6-7%, while also increasing the peak sales forecast for Zebrutinib by 4% to 5.4 billion.
Hillhouse HHLR Q3 hold positions: Chinese concept stocks hold an absolute dominant position, and the total market value of hold positions grew by more than 10%!
①HHLR Advisors, a subsidiary of Hillhouse Capital, saw its total market cap of US stocks holding positions grow by over 10% in the third quarter, with 9 of the top ten heavy positions being Chinese concept stocks; ②HHLR Advisors continued to hold heavy positions in Chinese concept stocks in the third quarter, with the market cap of Chinese concept stocks increasing from 85% in the second quarter to 93% in the third quarter.